Abstract:Background. Rapamycin is known to induce autophagy, promote cell survival and inhibit the progression of diabetic nephropathy (DN). Objectives. The aim of this study was to examine the role of autophagy in the treatment of DN with rapamycin to provide the basis for the DN treatment with rapamycin. Materials and methods. Human mesangial cells (HMC) were cultured in a constant temperature incubator with 5% CO2, at 37 degrees C and saturated humidity. Cells were divided into 5 groups and the 5-ethynyl2-deoxyuridine (EdU) cell proliferation assay was used to determine cell proliferation. Flow cytometry was used to determine cell apoptosis, while GFP-RFP-LC3 showed autophagy flow. Western blot was employed to detect the expression of autophagy-related proteins LC3-II/LC3-I and P62. Enzyme -linked immunosorbent assay (ELISA) was used to determine the contents of type IV collagen fiber (Col4), hyaluronic acid (HA) and laminin (LA) in the extracellular matrix (ECM). Results. Cell proliferation was the lowest in the hyperglycemic group. Additionally, the hyperglycemic group displayed the lowest number of autolysosomes compared to other groups. In contrast, the rapamycin group exhibited the highest number of autolysosomes. The LC3-II/LC3-I ratio was also the lowest in the hyperglycemic group, measuring 0.53 (0.50-0.58), while the expression level of P62 was significantly higher in that group at 0.98 (0.95-1.01) compared to other groups. Upon the introduction of rapamycin, the LC3-II/LC3-I ratio was significantly increased at 2.21 (1.95-2.21), and P62 was significantly decreased 0.38 (0.38-0.39) compared to the hyperglycemic group. Both changes were statistically significant, with p -values of 0.034 and 0.010, respectively. Enzyme -linked immunosorbent assay was employed to detect Col4, HA and LA content. The study findings demonstrated significantly higher levels of glucose in the hyperglycemic group in comparison to other groups. In contrast, the rapamycin group exhibited significantly lower levels of glucose than the hyperglycemic group, yet the difference was not statistically significant. Conclusions. Hyperglycemic can inhibit the autophagic activity of HMC, promote cell apoptosis, enhance ECM accumulation, and facilitate the DN progression. In contrast, rapamycin can elicit autophagy, decrease mesangial matrix proliferation, and therefore impede DN progression.

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Effects of rapamycin on podocytes of rats with diabetic nephropathy

Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin.

Effects of Rapamycin on Nephropathy of Diabetic Rats and Expressions of Vascular Endothelial Growth Factor and Its Receptor

Rapamycin Induces Autophagy and Reduces the Apoptosis of Podocytes under a Stimulated Condition of Immunoglobulin A Nephropathy

The Inhibitory Effect of Rapamycin on Toll Like Receptor 4 and Interleukin 17 in the Early Stage of Rat Diabetic Nephropathy

The Roles of Autophagy in the Treatment of Diabetic Nephropathy with Rapamycin

Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals is Associated with Suppressions of Mtor and ERK1/2 Signaling

Rapamycin Induces Glucose Intolerance in Mice by Reducing Islet Mass, Insulin Content, and Insulin Sensitivity

Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy.

Rapamycin inhibits mesenteric neo-angiogenesis in portal hypertensive rats

Rapamycin Protects Against Aristolochic Acid Nephropathy in Mice by Potentiating Mammalian Target of Rapamycin-Mediated Autophagy

Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in A Rat Model of Iga Nephropathy

Rapamycin ameliorates brain damage and maintains mitochondrial dynamic balance in diabetic rats subjected to middle cerebral artery occlusion

Rapamycin Inhibits Activation of AMPK-mTOR Signaling Pathway-Induced Alzheimer’s Disease Lesion in Hippocampus of Rats with Type 2 Diabetes Mellitus

Therapeutic Effect of Mtor Inhibitor Rapamycin in Early Phase Cirrhotic Portal Hypertension of Rats

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation

Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of Mtor Signaling in Interstitial Macrophages and Myofibroblasts